Digestive Disease Week.

antiviral agents, many patients face barriers to access. In our Advances in Hepatology column, Dr David E. Bernstein discusses factors that are restricting the use of these lifesaving therapies. A feature article by Drs Nicolas A. Villa and M. Edwyn Harrison describes the diagnosis, classification, and management of biliary strictures, a common complication of liver transplantation. Although biliary strictures are associated with significant morbidity and mortality after liver transplant, advances in endoscopic therapy and interventional radiology have improved outcomes by decreasing the need for surgical repair or retransplant. In another feature article, Drs Steven Naymagon and Thomas A. Ullman review the current techniques for surveillance of dysplasia in inflammatory bowel disease patients, with a focus on chromoendoscopy. The authors elucidate key points in the controversy over the best approaches to diagnosis and management. In our Advances in IBD column, Dr William J. Sandborn examines new targets for small molecules in inflammatory bowel disease. The broad classes for which new agents are currently in clinical development include Janus kinase inhibitors, such as tofacitinib; sphingosine-1-phosphate receptor modulators, such as RPC1063 (ozanimod); and SMAD7 antisense inhibitors, such as mongersen. In our Advances in GERD column, Dr Vic Velanovich discusses nonmedical treatment options, such as endoluminal and Nissen fundoplications, for gastroesophageal reflux disease. I hope to see you at DDW and hope that you enjoy this issue.